News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
HENLIUS (02696.HK) Serplulimab Injection Approved by European Commission for Two Additional Indications
HENLIUS (02696.HK) announced that the European Commission (EC) has recently approved two additional indications for its self-developed serplulimab injection (trade name in mainland...
Reset
Send
The window will close in 5 seconds
HENLIUS (02696.HK) Serplulimab Injection Approved by European Commission for Two Additional Indications
Close
Recommend
2
Positive
1
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Gold ETF share!

HENLIUS (02696.HK)  +0.150 (+0.223%)    Short selling $5.06M; Ratio 10.453%   announced that the European Commission (EC) has recently approved two additional indications for its self-developed serplulimab injection (trade name in mainland China: Hansizhuang; trade name in the European Union: HETRONIFLY).

The newly approved indications are: serplulimab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with PD-L1 combined positive score (CPS) e5, unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC); and serplulimab in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with EGFR mutation-negative, ALK- or ROS1-negative unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (nsNSCLC). The approvals mean that the two additional indications for serplulimab have been authorized in all European Union member states as well as Iceland, Liechtenstein and Norway (each a European Economic Area (EEA) country). (sl/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-15 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.